Roche Cuts Cost of Drug to Prevent Blindness in HIV Patients
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Roche is supporting greater access to one of its drugs to prevent blindness in people with HIV in developing nations by cutting its cost by up to 90 per cent. The pharma company reached an agreement with the Medicines Patent Pool to provide discounted Valcyte (valganciclovir) at discount to treat the viral infection treat cytomegalovirus (CMV) in HIV patients. The infection affects around 1 in 10 people living with HIV in low-and middle-income countries, according to Roche, and can lead to vision loss and an increased risk of death.
Help employers find you! Check out all the jobs and post your resume.
Roche is supporting greater access to one of its drugs to prevent blindness in people with HIV in developing nations by cutting its cost by up to 90 per cent. The pharma company reached an agreement with the Medicines Patent Pool to provide discounted Valcyte (valganciclovir) at discount to treat the viral infection treat cytomegalovirus (CMV) in HIV patients. The infection affects around 1 in 10 people living with HIV in low-and middle-income countries, according to Roche, and can lead to vision loss and an increased risk of death.
Help employers find you! Check out all the jobs and post your resume.